Articles

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany;Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Germany
Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany
Division of Cardiology, University of Heidelberg, Germany
Division of Nephrology, University of Heidelberg, Germany
Department of Neurology, University of Heidelberg, Germany
Division of Clinical Chemistry, University of Heidelberg, Germany
Coordination Center for Clinical Trials, KKS, Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany
Institute of Human Genetics, University Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany
Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Germany;Division of Cardiology, University of Heidelberg, Germany
Vol. 102 No. 8 (2017): August, 2017 https://doi.org/10.3324/haematol.2016.163246